We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App




Recurrent Disease Following DCIS Unrelated to Initial Lesions

By LabMedica International staff writers
Posted on 15 Jun 2022

Ductal carcinoma in situ (DCIS) is the most common form of pre-invasive breast cancer and, despite treatment, a small fraction (5% to 10%) of DCIS patients develop subsequent invasive disease. More...

While DCIS are generally low-grade lesions that do not progress, a small portion of patients do experience recurrence, even after treatment.

As many DCIS lesions will never progress to invasive disease, some women may receive intensive treatment without any clinical benefit. There is limited knowledge of whether invasive recurrences are clonally related to the initial DCIS disease, making accurate evaluation of the risk of progression and the assessment of the prognostic value challenging.

A large international team of medical scientists led by those at King’s College London (London, UK) included in a study 129 DCIS recurrence pairs; 95 had developed an ipsilateral invasive recurrence and 34 had an ipsilateral DCIS recurrence. In addition, 34 synchronous DCIS-IBC lesions identified from the Duke DCIS cohort and 14 with a subsequent invasive recurrence in the contralateral breast from the Sloane cohort were also included.

For DNA isolation, either macrodissection using a light microscope or laser microdissection (LMD) was performed. Sections (8 µm) were stained using nuclear fast red (macrodissection) or toluidine blue (LMD) and DCIS or invasive disease were separated from the normal tissue. Tumor DNA was extracted using the AllPrep DNA/RNA FFPE Kit (Qiagen, Hilden, Germany). WES of the paired DCIS with subsequent recurrence together with matched normal tissue was performed. Genomic DNA was used to generate sequencing libraries using the SureSelectXT Low Input library kit (Agilent Technologies, Santa Clara, CA, USA). Libraries were sequenced on a NovaSeq 6000 (Illumina, San Diego, CA, USA) multiplexing 16 tumor samples per lane.

The scientists reported that the number of shared mutations between the pairs varied, ranging from none to 112. Overall, 83% of the tumor pairs exhibited evidence of clonal relatedness, but 17% did not. Those four pairs had no shared mutations that they could detect. Similarly, a copy-number analysis of 62 tumor pairs found 71%to be clonally related, 27 % to be unrelated, and 2% ambiguous. Targeted sequencing of a subset of those pairs then indicated 51% were clonally related, including four that were considered unrelated by copy-number analysis, and 15% percent unrelated.

Analyses of tumor pairs in which the initial lesion was DCIS and the recurrent one was also DCIS found that 85%of those tumor pairs were related, 9% were unrelated, and 6% were ambiguous, suggesting that recurrent DCIS is likely to be due to residual disease that went undetected. The most commonly mutated genes included PIK3CA and TP53, while the most common amplicons affected 17q12, 17q21.1, and 11q13, and their analysis indicates that these events occurred at the early stages of DCIS, years before the invasive recurrence.

Elinor J. Sawyer. MD, PhD, a Professor of Clinical Oncology and co-senior author of the study, said, “Our study indicates we can no longer consider DCIS solely as a precursor, but rather also a risk factor for the development of invasive breast cancer later on in life. This important new information about DCIS biology and behavior, together with other findings, could change the way we manage and treat the condition in clinics in the future.” The study was published on June 9, 2022 in the journal Nature Genetics.

Related Links:
King’s College London 
Qiagen 
Agilent Technologies 
Illumina


New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
Host Response Immunoassay Test
MeMed BV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.